icon- folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Seattle, Washington
Feb 19-22 2023
 		Back grey_arrow_rt.gif
 
 
 
HEPATITIS DELTA INFECTION AMONG PERSONS LIVING WITH HIV
 
 
  CROI 2023 Feb 20-23
(ABSTRACT 8)
Charles Beguelin
University of Bern, Bern, Switzerland
 
webcast: https://www.croiwebcasts.org/console/player/51519?mediaType=slideVideo&
 
CROI: BULEVIRTIDE +/- PEG-IFN IN HIV/HBV/HDV CO-INFECTED PATIENTS IN REAL-LIFE SETTINGS - (03/22/23)
 
NATAP Hep Delta section
 
EASL: Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results From a Phase 3 Randomized, Multicenter, Parallel Design Study - (06/24/22)
 
HDV Treatment-Research - Hepatitis D (Delta) Course Review: Conference Reports: USA/Global Prevalence, Mortality-HCC Impact, PWIDs, Treatment, Screening, Patient Support - (01/13/23)

HDV